Ис­пользование пероксида водорода выдыхаемого воздуха для оценки эффективности терапии бронхиальной астмы

Exhaled hydrogen peroxide is a marker of airway inflammation. However, its utility for monitoring of asth­ma is still uncertain. The aim of this study was to assess the effect of short-acting β 2 -agonists and inhaled steroids on the hydrogen peroxide (H 2 0 2 ) concentration in expired breath condensate in asthmatic patients. Fifteen patients with moderate atopic asthma were treated with salbutamol as required for 2 weeks followed 12-week treatment with budesonide (Pulmicort Turbuhaler, 400 meg daily). The exhaled H 2 0 2 concentration as measured using a colorimetric assay (Gallati&Pracht, 1985). FEV 1 was assessed using dry spirometer. Airway hyperresponsiveness was considered as a provocative concentration of inhaled histamine causing the 20%-fall in FEV 1 (PD 20 ). The H 2 0 2 baseline level in the asthmatic patients (0.19±0.03 μ‎M) was elevated compared to healthy sub­jects (0.028±0.003, p<0.001). The exhaled H 2 0 2 concentration did not change during the treatment with salbutamol but it was diminished by Pulmicort Turbuhaler. This was associated with significant improvement in clinical symptom score, FEV 1 and PD 20 in asthma patients. We conclude that the short-acting β 2 -agonists do not influence the H 2 0 2 concentration in the exhaled air condensate of the asthma patients but the inhaled steroids decrease it. This may reflect different anti-inflam­matory activities of these medications.